List of Excipients in Branded Drug GLIPIZIDE AND METFORMIN HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing GLIPIZIDE AND METFORMIN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Zydus Lifesciences Limited	glipizide and metformin hydrochloride	65841-659	CELLULOSE, MICROCRYSTALLINE
Zydus Lifesciences Limited	glipizide and metformin hydrochloride	65841-659	CROSCARMELLOSE SODIUM
Zydus Lifesciences Limited	glipizide and metformin hydrochloride	65841-659	FERRIC OXIDE RED
Zydus Lifesciences Limited	glipizide and metformin hydrochloride	65841-659	HYPROMELLOSES

What are the Most Frequently-Used Excipients in GLIPIZIDE AND METFORMIN HYDROCHLORIDE?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	FERRIC OXIDE RED
2	HYPROMELLOSES

Glipizide and Metformin Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Glipizide and metformin hydrochloride immediate-release tablets are a mature fixed-dose combination with limited patent protection and established generic competition. The commercial opportunity is primarily in low-cost manufacturing, reliable content uniformity, dissolution performance, supply-chain control, and differentiated dosage strengths rather than in basic composition-of-matter exclusivity.

Metformin creates the dominant formulation challenge because it is present at a high dose, is hygroscopic, and can produce large tablets with difficult compression and dissolution characteristics. Glipizide is a low-dose, poorly soluble sulfonylurea that creates blend-uniformity and content-uniformity risks. A successful product must control both extremes in one tablet.

What is the FDA status of glipizide and metformin hydrochloride tablets?

Glipizide/metformin hydrochloride is an FDA-approved oral treatment for adults with type 2 diabetes whose glycemic control is inadequate with diet, exercise, or either component alone. The branded product was marketed as Metaglip by Bristol-Myers Squibb. The FDA-approved immediate-release strengths were:

Strength	Glipizide	Metformin hydrochloride	Typical administration
Low strength	2.5 mg	250 mg	Usually with meals
Intermediate strength	2.5 mg	500 mg	Usually with meals
High glipizide strength	5 mg	500 mg	Usually with meals

The original NDA was approved in 2002. The product was approved as a combination of previously known active ingredients, so it did not receive new chemical entity exclusivity. Current U.S. competition is based principally on abbreviated new drug applications, not on originator exclusivity.

FDA labeling identifies the major safety constraints as hypoglycemia from glipizide and gastrointestinal effects, lactic acidosis risk, and renal-function limitations associated with metformin. These risks directly affect excipient selection, tablet size, dose titration, and patient adherence (FDA, 2002; DailyMed, 2024).

What excipients are used in glipizide and metformin hydrochloride tablets?

Generic products commonly use conventional immediate-release tablet excipients. Exact compositions vary by manufacturer and strength.

Functional role	Common excipient options	Formulation purpose
Diluent and compression aid	Microcrystalline cellulose, lactose, dibasic calcium phosphate	Provides tablet mass and improves compactability
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Sodium starch glycolate, crospovidone, croscarmellose sodium	Promotes tablet breakup and drug release
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force and tooling adhesion
Wetting aid	Sodium lauryl sulfate or another surfactant	Can improve wetting of poorly soluble glipizide
Coating system	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Improves swallowability, appearance, and product identification

The key formulation issue is not whether a particular excipient is novel. It is whether the complete excipient system produces an immediate-release tablet that meets assay, content-uniformity, dissolution, hardness, friability, stability, and bioequivalence requirements.

How should metformin hydrochloride drive excipient selection?

Metformin hydrochloride is normally present at 250 mg or 500 mg per tablet. The high drug load makes the active ingredient itself a major contributor to tablet volume, flow, compression behavior, and dissolution.

Direct-compression strategy

Direct compression can reduce manufacturing cost and eliminate a granulation step. It is attractive when the selected metformin grade has acceptable flow and compactability and when glipizide can be distributed uniformly at low concentration.

A direct-compression formula typically requires:

• A high-quality microcrystalline cellulose or co-processed filler
• A low-level glidant to control flow
• A lubricant system that limits hydrophobic over-lubrication
• A robust preblend or ordered mixing process for glipizide
• Tight control of particle-size distribution and bulk density

The principal risk is segregation. Metformin and glipizide differ substantially in dose, particle properties, and density. A direct-compression process must demonstrate blend uniformity and uniformity of dosage units across the manufacturing run.

Wet-granulation strategy

Wet granulation can improve flow, reduce segregation, and increase tablet robustness. It also adds drying, solvent, equipment, and stability costs.

A practical design is to granulate the high-load metformin fraction while introducing glipizide through a controlled preblend or separate granulation stream. This approach can improve content uniformity but creates additional process complexity. Excessive granulation or over-drying may slow dissolution or cause tablet hardness to rise beyond the intended range.

Dry-granulation strategy

Roller compaction can reduce water exposure and may be useful when moisture sensitivity or thermal exposure limits wet granulation. It can also improve powder handling at commercial scale. The main risks are ribbon-density variability, fines generation, and altered dissolution after compaction.

How should glipizide drive excipient selection?

Glipizide is present at a low dose and has limited aqueous solubility. Its formulation risks are different from those of metformin.

The central objectives are:

1. Uniform distribution of glipizide throughout the metformin-rich matrix.
2. Adequate wetting and dissolution of glipizide.
3. Prevention of adsorption onto processing equipment or carrier particles.
4. Consistent release across the approved strength range.

Particle-size control is often more important than adding a large amount of surfactant. Micronized glipizide can improve dissolution but may worsen cohesion, electrostatic charging, and segregation. A controlled preblend with a suitable carrier can reduce these risks.

Sodium lauryl sulfate may improve wetting but can affect tablet strength, dissolution, gastrointestinal tolerability, and formulation robustness. Crospovidone or croscarmellose sodium can improve liquid penetration, but the disintegrant level must be balanced against the high metformin load and the risk of overly rapid tablet breakup.

What formulation development strategy is most commercially attractive?

For a conventional generic, the strongest base case is an immediate-release tablet using a simple, well-characterized excipient system.

Recommended development path

Development stage	Commercial objective	Main technical decision
Preformulation	Reduce development risk	Characterize particle size, hygroscopicity, flow, compactability, and solubility
Prototype screening	Identify robust formula	Compare direct compression, wet granulation, and dry granulation
Scale-up	Control cost and variability	Select a process with low segregation and manageable equipment requirements
Bioequivalence	Secure ANDA approval	Match dissolution and pharmacokinetic performance against the reference product
Commercial validation	Protect margins	Establish process controls for assay, CU, dissolution, hardness, and moisture
Lifecycle management	Differentiate the product	Explore modified strengths, packaging, or a 505(b)(2) formulation

A formula with fewer excipients may have a lower cost of goods, but the lowest-excipient formula is not automatically the most profitable. A slightly more expensive blend that eliminates segregation, capping, or dissolution failures can provide higher manufacturing yield and better supply reliability.

What commercial opportunities exist for glipizide and metformin hydrochloride?

Low-cost generic supply

The largest opportunity is a reliable generic product for markets where price and availability determine prescribing. The product is suitable for manufacturers with established tablet capacity, metformin sourcing, and diabetes-channel distribution.

Competitive advantage can come from:

• Lower tablet weight
• Fewer manufacturing steps
• Higher batch yield
• Stable supply of metformin hydrochloride
• Reduced packaging cost
• Consistent availability across all marketed strengths

Strength-specific market coverage

The three commonly marketed combinations do not have identical clinical and commercial roles. The 2.5/250 mg strength supports initial combination therapy or cautious titration. The 2.5/500 mg strength provides increased metformin exposure without increasing glipizide. The 5/500 mg strength is directed toward patients requiring a higher sulfonylurea dose.

Offering all strengths can improve formulary acceptance and pharmacy substitution. A single-strength launch may reduce initial complexity but can limit prescriber utility and channel coverage.

Contract manufacturing and private-label supply

The product is well suited to contract manufacturing because the active ingredients are established, the dosage form is conventional, and the market does not require biologics infrastructure. A manufacturer with spare high-volume tablet capacity can offer:

• Private-label diabetes products
• Regional distribution rights
• Hospital and institutional supply
• Authorized generic supply
• Multi-country dossiers using the same core process

The commercial value depends heavily on regulatory documentation, change-control discipline, and supply continuity. Buyers generally place more value on a clean inspection history and dependable delivery than on minor tablet-appearance differences.

Fixed-dose combination substitution

Fixed-dose combinations reduce pill burden, but the product competes with separate glipizide and metformin tablets, metformin extended-release products, and newer diabetes therapies. The main market is therefore cost-sensitive patients who remain appropriate candidates for a sulfonylurea-containing regimen.

The product is less attractive as a premium brand because newer agents, including SGLT2 inhibitors and GLP-1 receptor agonists, have stronger differentiation in weight, cardiovascular, or renal outcomes. A premium strategy would require a clear adherence, tolerability, or delivery advantage.

What patents protect glipizide and metformin hydrochloride products?

The active ingredients are long-established generic substances. Glipizide and metformin hydrochloride do not have commercially relevant unexpired composition-of-matter patents in the United States.

The original Metaglip exclusivity profile was tied to an old combination product and clinical-development exclusivity, not to a current blocking patent estate. The principal commercial pathway is an ANDA referencing the listed drug, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, labeling, manufacturing, and quality.

Protection category	Current commercial relevance
Glipizide composition patents	Expired or commercially nonblocking
Metformin composition patents	Expired or commercially nonblocking
Original fixed-dose combination protection	No material current barrier to routine generic entry
Formulation patents	Must be assessed product by product; no broad market barrier is evident
Method-of-use patents	Limited relevance for standard type 2 diabetes treatment
Manufacturing patents	Potentially relevant only to a specific process or formulation
Regulatory exclusivity	No current NCE exclusivity expected for the mature combination

The FDA Orange Book should be used to confirm the live listing status of the reference product and any listed patents before an ANDA filing or Paragraph IV certification. Patent numbers should not be assumed from historical product literature because listed patents can expire, be delisted, or become irrelevant to a proposed generic formulation (FDA, 2024a).

What is the Paragraph IV and generic-entry risk?

Generic entry risk is high because:

• The active ingredients are old.
• The dosage form is an immediate-release tablet.
• The reference product has no meaningful NCE barrier.
• Excipients are generally conventional and pharmaceutically acceptable.
• Bioequivalence can normally be addressed through standard ANDA methods.

A Paragraph IV certification would be relevant only if an unexpired Orange Book patent were listed against the reference product. For a conventional immediate-release generic, the more important risks are technical and regulatory:

• Failure to demonstrate content uniformity for low-dose glipizide
• Dissolution mismatch caused by formulation changes
• Tablet-size or swallowability problems
• Inadequate stability under high humidity
• Inconsistent metformin assay or degradation control
• Manufacturing deviations during scale-up

What FDA regulatory pathway applies?

A standard generic would normally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must show pharmaceutical equivalence and bioequivalence to the reference product. The product must also meet applicable current good manufacturing practice requirements and use inactive ingredients that are acceptable for the route and dosage form.

A 505(b)(2) strategy could be considered for a genuinely differentiated product, such as:

• Modified release
• A novel tablet architecture
• A liquid or dispersible dosage form
• A formulation with a materially different administration profile
• A product supported by new clinical or pharmacokinetic data

The 505(b)(2) route would carry higher development cost and potentially greater regulatory complexity. It is difficult to justify for a standard immediate-release tablet unless the applicant has a clear commercial advantage.

How strong is the patent estate and manufacturing IP position?

The patent estate is weak for a conventional glipizide/metformin hydrochloride tablet. The defensible value lies in manufacturing execution rather than exclusionary patent rights.

Potential manufacturing know-how includes:

• Glipizide preblend sequence
• Granulation endpoint control
• Moisture-management conditions
• Lubrication time and speed
• Compression-force windows
• Tooling configuration for a large-dose tablet
• Packaging that protects against humidity
• Process controls for segregation and weight variation

A process patent could have value if it produces a measurable, non-obvious improvement, but routine optimization of excipient levels or mixing order may not create durable exclusivity. Trade secrets and validated process capability are likely to be more commercially useful than a narrow formulation patent.

How does this product compare with separate glipizide and metformin tablets?

Factor	Fixed-dose combination	Separate tablets
Pill burden	Lower	Higher
Dose flexibility	Lower	Higher
Manufacturing complexity	Higher because two actives must be controlled	Lower per product
Adherence potential	Better for stable regimens	Better for individualized titration
Generic competition	Strong	Very strong
Commercial differentiation	Limited	Limited
Formulation risk	High content-uniformity and dissolution coordination	More manageable per active

The fixed-dose product is most attractive after the patient’s glipizide and metformin doses are established. It is less suitable when either component requires frequent independent adjustment.

Key Takeaways

• Glipizide/metformin hydrochloride is a mature immediate-release combination with high generic-entry risk and limited current patent protection.
• Metformin drives tablet size, hygroscopicity, compression, and manufacturing economics.
• Glipizide drives low-dose content uniformity, blend segregation, and dissolution risk.
• A direct-compression formula may offer the lowest cost, but wet or dry granulation may provide better process robustness.
• The strongest commercial opportunity is a reliable, low-cost generic covering the 2.5/250 mg, 2.5/500 mg, and 5/500 mg strengths.
• Manufacturing know-how, humidity protection, process capability, and supply reliability are more valuable than broad patent exclusivity.
• A standard ANDA is the likely regulatory route. A 505(b)(2) strategy is relevant only for a genuinely differentiated dosage form or release profile.
• The main competitive threat is substitution by separate tablets, metformin extended-release products, and newer diabetes therapies.

FAQs

Is glipizide and metformin hydrochloride still commercially attractive?

Yes, primarily as a low-cost generic or contract-manufactured product. Premium pricing is difficult because the ingredients and immediate-release dosage form are mature.

Which excipient is most important for glipizide uniformity?

No single excipient controls uniformity. Particle-size control, preblending, carrier selection, mixing sequence, and segregation control are usually more important than the choice of one disintegrant or lubricant.

Can glipizide/metformin hydrochloride be developed as an extended-release product?

Yes, but that would be a materially different development program. It would require release-control design, additional dissolution development, pharmacokinetic assessment, and a more complex regulatory strategy.

Does metformin hydrochloride create a humidity-related stability risk?

Yes. Metformin-containing tablets should be evaluated under controlled humidity and packaged with a moisture-protective system appropriate to the stability data.

Are biosimilars relevant to glipizide and metformin hydrochloride?

No. Both active ingredients are small-molecule drugs. Competitive products use generic-drug pathways rather than biosimilar pathways.

References

1. DailyMed. (2024). Glipizide and metformin hydrochloride tablets: Prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2002). Metaglip (glipizide and metformin hydrochloride) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024b). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.

5. United States Pharmacopeia. (2024). General chapters: <905> Uniformity of dosage units and <711> Dissolution. United States Pharmacopeial Convention.

6. U.S. Food and Drug Administration. (2024c). Inactive ingredient database. FDA.